United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $578.65, for a total transaction of $5,497,175.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $23,442,847.45. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

United Therapeutics Stock Performance

UTHR opened at $575.79 on Friday. The firm’s fifty day moving average is $556.50 and its two-hundred day moving average is $506.65. The firm has a market cap of $24.44 billion, a PE ratio of 21.25, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter last year, the business posted $6.63 earnings per share. Equities analysts forecast that United Therapeutics Corporation will post 27.64 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Torren Management LLC acquired a new stake in United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management increased its stake in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC acquired a new stake in United Therapeutics in the 4th quarter valued at $31,000. International Assets Investment Management LLC increased its stake in United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB increased its stake in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

UTHR has been the topic of a number of research analyst reports. TD Cowen raised their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. UBS Group raised their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.